Hospital mortality in COVID-19 patients in Belgium treated with statins, ACE inhibitors and/or ARBs.

For treatment with statins alone (177 matched sets) and ACEIs/ARBs alone (90 matched sets), the adjusted ORs were 0.56 (95% CI 0.39–0.93, p = .024, SMD = 0.08) and 0.52 (95% CI 0.23–1.17, p = .11, SMD = 0.006), respectively ( Table 3 ). Using Gray’s test, the CIF, which accounted for the difference in mortality between the statins + ACEIs/ARBs vs no statins and no ACEIs/ARBs, was highly significant; p = .0040 ( Figure 2(c )).

also in 132,142 other papers

Similarly, those taking statins, ACEIs and ARBs had fewer episodes of serious COVID-19 requiring hospitalization, but again the results failed to reach statistical significance.

also in 6,035 other papers